Compare abrdn Income Credit Strategies Fund (ACP) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Neurocrine Biosciences Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.11 (market cap $637.39M), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 26.3× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 18.31% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| ACP | NBIX | |
|---|---|---|
Market Cap | $637.39M | $16.76B |
Sector | Financials | Health |
52-Week High | $5.98 | $185.50 |
52-Week Low | $5.01 | $123.10 |
Dividend Yield | 18.31% | — |
Enterprise Value | — | $16.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.08, up 0.4% today, with a bearish technical signal from moving averages and a neutral stance from oscillators. The stock shows a low P/E of 7.7 and P/B of 0.9, indicating potential undervaluation, while net income margin remains high at 95.31%. Recent news highlights dividend declarations but also concerns over distribution sustainability from Seeking Alpha (2026-05-29).
The outlook is mixed: attractive valuation and dividends offer income appeal, but technical weakness and high distribution reliance pose risks. Investors should weigh the fund's high yield against credit spread tightness and leverage exposure noted in analyst reports.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
